US drugmaker Eli Lilly raises its revenue outlook as profits surge on strong demand for weight-loss drugs

Eli Lilly raised its full-year revenue forecast after weight-loss drug sales drove a sharp rise in profits, with the pharmaceutical giant now expecting stronger top-line performance than previously guided. The company trimmed its profit outlook, however, after absorbing charges related to a recent deal.

Demand for Lilly's weight-loss treatments has outpaced earlier expectations, forcing a second upward revision to revenue guidance this year.

The profit view was cut to account for one-off deal charges, though underlying trading momentum remains strong.

The results cement Lilly's position as one of the biggest beneficiaries of the global weight-loss drug boom.